Summary
Boston Scientific Corporation's 2003 10-K report highlights a company firmly established in the medical device market, focused on less-invasive medicine. A significant strategic emphasis is placed on the burgeoning drug-eluting stent (DES) market, particularly with the upcoming U.S. launch of the TAXUS™ paclitaxel-eluting coronary stent system, expected to drive substantial revenue growth. The company leverages a broad product portfolio across interventional cardiology and endosurgery, supported by a robust business strategy centered on innovation, clinical excellence, product diversity, operational efficiency, and focused marketing. Despite a competitive landscape and ongoing patent litigation, Boston Scientific is positioning itself for continued leadership and expansion, particularly in high-growth areas like cardiovascular interventions.
Key Highlights
- 1Strong market position in interventional medicine, with a broad portfolio of medical devices.
- 2Significant strategic focus on the drug-eluting stent (DES) market, with the TAXUS™ stent poised for U.S. launch, anticipating substantial revenue growth.
- 3Cardiovascular products accounted for approximately 72% of net sales in 2003, indicating a strong reliance on this segment.
- 4The company is actively engaged in research and development, investing approximately $450 million in 2003, representing about 13% of net sales.
- 5Boston Scientific is pursuing growth through strategic acquisitions and alliances, investing over $350 million in approximately 25 initiatives in 2003.
- 6The company operates globally, with international sales representing approximately 45% of net sales in 2003.
- 7Significant ongoing patent litigation with key competitors, including Johnson & Johnson and Guidant Corporation, presents potential risks and uncertainties.